Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer

Keisuke Okuno1,2†, Rachana Garg1†, Yate-Ching Yuan3, Masanori Tokunaga2, Yusuke Kinugasa2 and Ajay Goel1,4*

1 Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, CA, United States, 2 Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan, 3 Translational Bioinformatics, Center for Informatics, City of Hope, Duarte, CA, United States, 4 City of Hope Comprehensive Cancer Center, Duarte, CA, United States

Background: Naturally occurring dietary botanicals offer time-tested safety and anti-cancer efficacy, and a combination of certain compounds has shown to overcome the elusive chemotherapeutic resistance, which is of great significance for improving the mortality of patients with colorectal cancer (CRC). Accordingly, herein, we hypothesized that berberine (BBR) and oligomeric proanthocyanidins (OPCs) might regulate synergistically multiple oncogenic pathways to exert a superior anti-cancer activity in CRC.

Methods: We performed a series of cell culture studies, followed by their interrogation in patient-derived organoids to evaluate the synergistic effect of BBR and OPCs against CRC. In addition, by performing whole genome transcriptomic profiling we identified the key targeted genes and pathways regulated by the combined treatment.

Results: We first demonstrated that OPCs facilitated enhanced cellular uptake of BBR in CRC cells by measuring the fluorescent signal of BBR in cells treated individually or their combination. The synergism between BBR and OPCs were investigated in terms of their anti-tumorigenic effect on cell viability, clonogenicity, migration, and invasion. Furthermore, the combination treatment potentiated the cellular apoptosis in an Annexin V binding assay. Transcriptomic profiling identified oncogene MYB in PI3K-AKT signaling pathway might be critically involved in the anti-tumorigenic properties of the combined treatment. Finally, we successfully validated these findings in patient-derived CRC tumor organoids.

Conclusions: Collectively, we for the first time demonstrate that a combined treatment of BBR and OPCs synergistically promote the anti-tumorigenic properties in CRC possibly through the regulation of cellular apoptosis and oncogene MYB in the PI3K-Akt signaling pathway.

Keywords: colorectal cancer, berberine, oligomeric proanthocyanidins, grape seed extract, synergistic effect, apoptosis, MYB, PI3K-Akt signaling pathway
INTRODUCTION

Colorectal cancer (CRC) is one of the most common malignancies worldwide, and currently ranks fourth in disease incidence and the second leading cause of cancer-related deaths, with an estimated 104,270 new cases and 52,980 deaths in 2021 (1). Systemic chemotherapy remains the backbone and one of the best therapeutic options for CRC patients with distant metastasis or recurrence. Although 5-fluorouracil based therapy is the standard of care chemotherapeutic intervention in patients with CRC (2, 3), a large majority of CRC patients tend to acquire resistance and become chemoresistant to such treatments. The acquisition of chemo-resistance is primarily due to compensatory overload or emergence of mutations in chemotherapy-induced targeted pathways in a clone of cancer cells (4, 5), which renders these patients unresponsive to subsequent drugs (6, 7). Accordingly, a growing school of thought is that instead of the use of single agents, combination therapies by employing more than one simultaneous drugs that can modulate multiple pathways might enhance the overall therapeutic efficacy as it mitigates the opportunity to develop chemo-resistance to a single therapy. In other words, the development of chemoresistance presents a major challenge in the management of CRC, and an optimal combination of various therapeutic modalities is a growing area of research to thwart this clinical challenge.

In recent years, accumulating body of data have shown that active principles within various naturally-occurring dietary botanicals offer a time-tested safety and anti-cancer efficacy (8–16). While this list of compounds is quite large, including some of the research undertaken by our research team on curcumin (17–24), Boswellic acids (19, 25, 26), andrographis extract (27–29) and oligomeric proanthocyanidins (OPCs) (27, 30–33). In this regard, OPCs and berberine (BBR), have recently been actively studied for their anti-tumorigenic properties in CRC and other human cancers (16, 27, 30–33). BBR is a small molecule isoquinoline alkaloid extracted from the rhizomes of Berberis including Coptidis rhizome and Amur corktree bark and was traditionally used to treat a variety of conditions including bacterial diarrhea in China and native America (16, 34). However, recent studies have shown their diverse pharmacological anti-cancer effects against CRC through a multitude of regulatory mechanisms, including the Wnt signaling pathway, SCA/PsREBP-1 pathway, and β-catenin signaling pathway (35–37). On the other hand, OPCs are a class of polyphenols that are frequently present in a variety of purple or red pigmented plants, including their heavy abundance in the grape seeds. The OPCs also possess anti-cancer properties, and some of the work from our group in the past has demonstrated that their anti-tumorigenic activity in CRC is mediated through cell-cycle dynamics, cancer stem cells, and regulation of ABC drug transporters (30, 32, 33).

A more recent study revealed existence of synergism between BBR and OPCs in patients with type 2 diabetes mellitus (38). This report demonstrated that OPCs inhibited the efflux of BBR and simultaneously increased its cellular uptake by the epithelial cells. Furthermore, OPCs also potentiated the therapeutic efficacy of BBR in mice with diabetes, without causing any harmful adverse effects. On similar lines, our recent research has also demonstrated the cooperative and synergistic effects of OPCs with several other natural compounds, such as curcumin and andrographolide in CRC (27, 31). Furthermore, several previous studies demonstrated the BBR’s synergistic anti-cancer effect with other natural compounds and chemotherapeutic drugs (39–44). In view of these accumulating evidence, we hypothesized that BBR and OPCs might synergistically regulate multiple oncogenic cell signaling pathways to exert a superior anti-cancer activity in CRC. Furthermore, a combination of BBR and OPCs might appropriately also mitigate the likelihood for development of chemoresistance in this malignancy.

Herein, for the first time, we performed a systematic series of experiment in various cell lines, followed by their interrogation in patient-derived organoids to evaluate the synergistic anti-tumorigenic effects of BBR and OPCs in CRC. In addition, we performed whole genome transcriptomic profiling to decipher the molecular mechanisms and key growth regulatory pathways regulated by the combined treatment with BBR and OPCs in this malignancy.

MATERIALS AND METHODS

Cell Culture and Materials

Human colorectal cancer cell lines (RKO and HT29) were purchased from the American Type Culture Collection (Manassas, VA). NCM460 was obtained from INCELL Corporation (San Antonio, TX). All cell lines were tested and authenticated using a panel of genetic and epigenetic markers for their genomic authenticity and tested for mycoplasma on a regular basis. The cell lines were cultured in Dulbecco’s Medium Eagle’s medium (DMEM; Gibco, Carlsbad, CA) containing 10% fetal bovine serum, 0.03% EDTA (Invitrogen, Carlsbad, CA). Grape seed-OPCs (VX1 extract, EuroPharma USA, Green Bay, WI) and berberine (Berberine HCL, EuroPharma USA, Green Bay, WI) were dissolved in DMSO. Both compounds were diluted to appropriate experimental concentrations in culture medium.

Cell Viability, Proliferation, Invasion and Wound Healing Assays

Cells were plated at a density of 3-5 x 10³ cells per well in 96-well plates under each culture conditions, and incubated with various concentrations of BBR, OPCs, and their combination for 48 hours. We used uniform DMSO concentrations between each treatment groups, including the untreated group. Cell proliferation was measured using Cell Counting Kit-8 (CCK-8) assays (Dojindo, Kumamoto, Japan) as described previously (28). To assess the synergism between BBR and OPCs, the combination index (CI) was calculated using the Chou-Talalay equation (45) at 50% inhibitory concentration. A CI of less than 1.0 was considered to be a synergistic interaction.

For the invasion assay, cells (3-5 x 10⁴ cells) following treatment with BBR, OPCs, and their combination for 48 hours were grown in 24-well transwell chambers (8-μm pore size) coated with Matrigel (BD Biosciences, Franklin Lakes, NJ).
After 48 hours, invading cells were detected by Diff-Quik staining. The wound healing assay was performed as described previously (33). Cells were seeded in 12-well plates and grown to 80% confluence. Wounds were created by scraping monolayer cells with a 200-µl pipette tip, and treated with BBR, OPCs, and their combination. 24 hours after scratching, treated and control cells were observed with a microscope.

**Apoptosis and Colony Formation Assays**

For the Annexin V binding assay, cells were seeded in 6-well plates, followed by treatment with BBR, OPCs, and their combination for 48 hours. The assay utilizes Annexin V to detect phosphatidylserine on the external membrane of apoptotic cells. After treatment, cells were harvested, and 100 µl of cell suspension was added to 100 µl of the Muse Annexin V & Dead Cell reagent (Millipore Corp, Billerica, MA). The apoptotic cell fraction was measured using the Muse Cell Analyzer (Millipore Corp) according to the manufacturer’s instructions. The colony formation assay was performed as described previously (25). For this assay, 5 x 10^2 cells were seeded in 6-well plates, followed by treatment with BBR, OPCs, and their combination for 48 hours. After 7 days, cells were fixed by 100% methanol and stained by 1% crystal violet. The number of colonies with more than 50 cells were counted manually, and the relative change was determined.

**Measurement of BBR Uptake**

BBR emits a yellowish fluorescence (excitation: 488nm, emission: 564nm) (46, 47), and its uptake was examined using the Infinite M1000 microplate reader (Tecan Trading AG, Männedorf, Switzerland) and confocal microscopy. The cells were treated with BBR, OPCs, or their combination for 24 hours, and washed two times with cold phosphate buffered solution (PBS) before measurement. BBR autofluorescence was imaged using 488nm excitation and 564nm emission. Cells were observed under 200x magnification using a fluorescent microscope.

**RNA Extraction and Quantitative Reverse Transcription PCR (qRT-PCR)**

Total RNA was extracted from cells using the Qiagen miRNeasy Kit (Qiagen, Hilden, Germany), and reverse transcribed to complementary DNA (cDNA) using a high-capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA). The qRT-PCR assays were performed using a SensiFAST SYBR Lo-ROX Kit (Bioline, London, United Kingdom) and the QuantStudio 6/7 Flex RT-PCR System (Applied Biosystems, Foster City, CA). The β-actin gene was used as an internal control. The delta Ct method, where delta Ct is the difference in Ct values between the abundance of target transcripts and the internal control, was used for quantification (48). The primers used in the present study were described in Supplementary Table S1.

**Genome-Wide RNA Sequencing and Analysis**

Genome-wide RNA sequencing was performed as described previously (30). Total RNA was isolated from RKO and HT29 cells treated with DMSO (Control), BBR, and OPCs for 24 hours using the Qiagen miRNeasy Kit (Qiagen, Hilden, Germany). Next-generation sequencing library construction was performed by the TruSeq RNA library kit (Illumina, Chicago, IL), and the quality of each library was assessed through a High Sensitivity DNA Kit (Agilent, Los Angeles, CA). Libraries were pooled together using a Pippin HT instrument (Sage Science, Beverly, MA). Efficiency of size selection was assessed by a High Sensitivity DNA Kit (Agilent). The pooled libraries were quantified by qRT-PCR using the KAPA Library Quantification Kit, Universal (KAPA Biosystems, Philadelphia, PA) before sequencing on an Illumina HighSeq 2500 with single-end 75 base read lengths. Fastq files were trimmed using Flexbar to remove 3’ bases with quality scores lower than 30 before alignment, and the trimmed reads were mapped to human genome version GRCH38 downloaded from GENCODE57 (49) using HISAT258 (50) to generate alignment files in bam format. Samtools name-sorted bam files (51) were processed using htseq-count to summarize gene level counts (52). DESeq 2 was used for differential gene expression analysis of RNA-sequencing read counts (53).

The raw expression data was analyzed using the Partek Genomic Suite (Build version 10.0.21.0929; Partek Inc., St. Louis, MO). A given gene was considered differentially expressed if it had an FDR step-up p < 0.05 and a fold-change ≥ ±1.5. The heatmap was generated using the Partek Genomic Suite, and the molecular pathways of the differentially expressed genes were analyzed using the KEGG and Partek pathway (Partek, St. Louis, MO) analytical methods. The data was subsequently analyzed for enrichment of GO terms and the KEGG pathways; a pathway was considered significantly enriched if the enrichment score is > 3 and p < 0.05.

**Western Blotting**

Western blotting (WB) for total protein extracted for cells was performed as described previously (28). Primary antibodies against Bax (1:1000, #5023; Cell Signaling Technology), Bcl-2 (1:1000, #15071; Cell Signaling Technology), Akt (1:1000, #4691; Cell Signaling Technology), and phospho-Akt (Ser473) (1:1000, #4060, Cell Signaling Technology) were used. β-actin (1:1000, #58169; Cell Signaling Technology) were used as an internal control of WB. The relative protein levels were quantified by using the ImageJ 1.47v software (http://imagej.nih.gov/ij/index.html).

**Transfection of Small Interfering RNA**

For these experiments, 1 x 10^6 cells were reverse transfected with the MYB siRNA (Thermo Fisher Scientific, Waltham, MA) or negative control siRNA (Thermo Fisher Scientific, Waltham, MA) using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific, Waltham, MA) and then seeded in 6-cm plate. 24-48 hour after transfection, cells were used for the total RNA extraction, total protein extraction, and the other assays.

**Patient-Derived CRC Tumor Organoids**

Human primary CRC tissues were obtained from patients with CRC enrolled at Baylor University Medical Center, Dallas, TX. With approval from the ethics committees of the institution, a written informed consent was obtained from all patients. Patients were anonymously coded in accordance with ethical guidelines, as instructed by the Declaration of Helsinki. CRC tumor organoids
were cultured using a modified protocol described previously (32). The CRC tumors were incubated in Gentle Cell Dissociation Reagent (STEMCELL Technologies, Vancouver, BC, Canada), and resuspended in DMEM/F-12 with 15mM HEPES (STEMCELL Technologies). Tissues were minced and digested with collagenase solution (5ml of above medium with 75µl collagenase, 124µg/ml disase type II, and 0.2% Primocen), and then suspended in 100µl of Matrigel (Corning, Tehama County, CA) with 100µl of IntestiCult™ Organoid Growth Medium (#06010, STEMCELL Technologies). The organoids were suspended to four wells such that forms a dome, and then, 750µl of IntestiCult™ Organoid Growth Medium were added to each well. The organoids were randomly assigned into four groups and treated with appropriate concentrations of BBR (20µg/ml), OPCs (20µg/ml), and their combination (BBR: 20µg/ml, OPCs: 20µg/ml). The control organoids were treated with a very low concentration of DMSO. Seven days after growth in the culture medium, the organoids that were about 500 microns in diameter were observed and counted under a bright-field microscope. And then the organoids were harvested by Gentle Cell Dissociation Reagent, and harvested organoids were used for total RNA extractions.

**Statistical Analysis**

All experiments were conducted as three independent technical triplicates. All data were expressed as mean ± standard deviation (SD). Two-sided Student’s t test was used to analyze differences between continuous values of each independent group. All P values were two-sided, and P < 0.05 was considered statistically significant. All statistical analyses were performed using EZR (34), which is a graphical user interface for R (R Foundation for Statistical Computing, Vienna, Austria, version 4.0.3) designed to add statistical functions and is frequently used in biostatistics.

**RESULTS**

**OPCs Exhibited a Synergistic Anti-Tumorigenic Effect With BBR in Inhibiting Cell Proliferation, Colony Formation, Migration, and Invasion Through Enhanced Cell Apoptosis**

To evaluate if OPCs exhibit any synergistic anti-tumorigenic effects with BBR in CRC cells, we first investigated the effects of each compound individually (0, 20, 40, 60, 80, and 100µg/ml), and their combination in RKO and HT29 cells. The median IC25 and IC50 of the combination treatment in both cell lines were 11.38 and 23.87µg/ml, respectively, therefore, following experiments were performed at a concentration of 20µg/ml, which is approximately IC50 of a combination treatment. In support of our original hypothesis, the combination of BBR and OPCs demonstrated notably superior anti-proliferative effects in both cells (Figure 1A). To assess the synergy between BBR and OPCs, the CI was calculated using the Chou-Talalay equation (45) at 50% inhibitory concentration, with 0.74 and 0.64 value observed in RKO and HT29 cells, respectively (Supplementary Figure S1).

Because a CI of less than 1.0 was considered to be synergistic, these data indicated a synergistic anti-tumorigenic effect of BBR and OPCs in CRC cells. Interestingly, combination treatment was safe and did not affect cell viability in normal colon epithelial cell line NCM460 (Supplementary Figures S2A, B). Furthermore, the colony formation assays following treatment with BBR (20µg/ml), OPCs (20µg/ml), and their combination (BBR: 20µg/ml, OPCs: 20µg/ml) demonstrated that the combined treatment resulted in a significantly higher reduction of clonogenicity than either treatment alone in CRC cells (fold change [FC] = 0.22 vs BBR alone, P = 0.01; FC = 0.21 vs OPCs alone, P = 0.01 in RKO cells; FC = 0.51 vs BBR alone, P = 0.04; FC = 0.35 vs OPCs alone, P = 0.04 in HT29 cells; Figure 1B).

Next, we assessed the ability of BBR and OPCs to inhibit cellular migration and invasion, which is critical for cancer progression and metastases. With regards to the wound healing and invasion assay, BBR and OPCs significantly decreased cell migration and invasion compared to control cells, while the combination treatment of these compounds significantly enhanced these effects for their ability to inhibit cell migration (in RKO cells; vs BBR alone, P = 0.15; vs OPCs alone, P = 0.01; In HT-29 cells, vs BBR alone, P = 0.05; vs OPCs alone, P < 0.01; Figure 1C) and invasion (vs BBR alone, P = 0.03; vs OPCs alone, P < 0.01 in RKO cells; vs BBR alone, P < 0.01; vs OPCs alone, P < 0.01 in HT29 cells; Figure 1D).

To clarify the underlying mechanism that orchestrated the enhanced efficacy for the combination treatment of BBR and OPCs in reducing the cell viability and clonogenicity, we evaluated their combinatorial impact on apoptotic rates by an Annexin V binding assay. Compared to the untreated group, BBR significantly increased the rates of apoptosis, whereas the combined treatment with BBR and OPCs further enhanced the apoptotic potential of BBR (Figure 2A). Furthermore, for the expression of apoptosis related genes, the combination treatment significantly up-regulated Bax and down-regulated Bcl-2 at the mRNA and protein level (Figures 2B, C). Taken together, these data confirm that OPCs potentiated the anti-tumorigenic effect of BBR through increased apoptosis and other key cancer cell death mechanism in CRC cells.

**OPCs Increased the Cellular Uptake of BBR in CRC Cells**

To evaluate the mechanism of synergy, we examined whether OPCs affect the cellular uptake of BBR in CRC cells. Because the IC25 and IC50 concentration of the combination treatment was approximately 10 and 20µg/ml, respectively (Figure 1A), RKO and HT29 cell lines were treated with BBR (10 and 20µg/ml) and various concentration of OPCs (10 and 20µg/ml) for 24 hours. Using BBR’s yellowish fluorescence (excitation: 488nm, emission: 564nm), the cellular uptake of BBR was visualized by the multimode microplate reader and confocal microscopy. Interestingly, we noted that OPCs promoted the fluorescence intensity of BBR in both RKO and HT29 cells, while the combination of OPCs exhibited significantly higher uptake of BBR than BBR alone in a concentration-dependent manner; the combination of 20µg/ml OPCs revealed 2.91 and 2.28 times higher uptake of BBR in RKO and HT29 cells, respectively (P = 0.04 and P = 0.03, respectively, vs BBR: 20µg/ml alone;
These data suggest that OPCs facilitate increased cellular uptake of BBR in CRC cells, supporting the previous observation made in type 2 diabetes mellitus (38).

Transcriptomic Profiling Revealed That BBR and OPCs Modulated Key Cancer-Associated Pathways

To unravel the molecular mechanisms underlying the anti-tumorigenic properties of the combination treatment, we examined the genome-wide transcriptomic changes induced by BBR and OPCs in RKO and HT29 cells using the Partek Genomic Suite. The treatment of BBR resulted in 2851 up- or down-regulated (> 1.5-fold) probes in RKO cells, and 7372 up- or down-regulated (> 1.5-fold) probes in HT29 cells. We also detected that 621 and 617 up- or down-regulated (> 1.5-fold) probes by the treatment of OPCs in RKO and HT29, respectively. Among them, 108 and 336 genes were altered by both treatments in RKO and HT29, respectively (Figures 4A, B).

Next, we examined Gene Ontology enrichment analysis of these up- or down-regulated genes using the KEGG and Partek pathway analytical methods. This analysis revealed that PI3K-Akt signaling pathway was one of the key pathways that was commonly abrogated in both RKO and HT29 cells (enrichment score: 5.67, p < 0.01 in RKO; enrichment score: 4.20, p = 0.01 in HT29), because PI3K-Akt signaling pathway was the only pathway that was common among the top 10 pathways in both cells (Figures 4C, D). Since the expression of CDKN1A, F2R, FGFI9, ITGB7, and MYB were up- or down-regulated by both treatments in each cell line (Figure 4E), we next validated the expression of these 5 genes by qRT-PCR, and the results were consistent with the sequencing data (Figure 4F and Supplementary Figure S3). Furthermore, the protein expression level of Akt, which is one of the key genes in the PI3K-Akt signaling pathway, was significantly inhibited by combined treatment of BBR and OPCs in both cells. In addition, combined treatment attenuated phosphorylation of Akt at Ser473, which indicated that the PI3K-Akt signaling...
pathway is the key pathway regulated by combined treatment of BBR and OPCs (Figure 4G). For the combination treatment, the expression of only MYB were significantly down-regulated compared to control and BBR in both cells. MYB emerged as one of the key regulators of this anti-cancer activity. MYB, encodes three types of oncoprotein that function as a transcription regulator, is considered to be an oncogene, and is involved in the regulation of apoptotic process (55–58) – hence, supporting the apoptotic potential of the combination treatment (Figures 2A–C). Furthermore, MYB is often up-regulated in patients with CRC (59, 60), and recently have gained increased attention as a potential and novel therapeutic target in cancer (61, 62). Based upon these findings, among these five genes, we focused on MYB as a target of the combined treatment with BBR and OPCs and selected this gene for subsequent experiments.

SiRNA-Mediated Knockdown of MYB Exhibited the Anti-Tumorigenic Effects by Inhibiting Cell Proliferation and Migration in CRC Cells

To address the role of MYB in the anti-tumorigenic properties of the combination treatment in CRC cells, we next performed siRNA-based knockdown of MYB in RKO and HT29 cells. The expression of MYB at the mRNA levels was inhibited 24 hours after transfection of its siRNA (Figure 5A). As for series of proliferation and wound healing assays, knockdown of MYB significantly inhibited cell proliferation ($P = 0.01$ in RKO cells; $P = 0.02$ in HT29 cells; Figure 5B) and migration ($FC = 0.37$, $P = 0.05$ in RKO cells; $FC = 0.42$, $P = 0.04$ in HT29 cells; Figure 5C) in RKO and HT29 cells. We also evaluated its impact on apoptotic rates via an Annexin V binding assay to further clarify that knockdown of MYB reduced the cell viability and migration. Compared to CRC cells transfected negative control siRNA, knockdown of MYB significantly increased the rates of cellular apoptosis ($FC = 1.78$, $P = 0.04$ in RKO cells; $FC = 1.50$, $P = 0.03$ in HT29 cells; Figure 5D). Moreover, knockdown of MYB significantly up-regulated Bax expression and down-regulated Bcl-2 expression at the mRNA and protein levels (Figures 5E, F). Taken together, these data suggest that MYB plays an important role in cancer progression and metastases through regulation of cellular apoptosis, and this gene is critically involved in the anti-tumorigenic effects of the combined treatment with BBR and OPCs.

The Combination of BBR and OPCs Synergistically Inhibited the Growth in Patient-Derived Organoids

Tumor organoid model and 3D primary cultures are physiologically superior to the conventional monolayer cultured cells for the study of anti-cancer agents (63). Thus, in
order to further support our cell culture findings, we finally utilized a tumor-derived organoid model from patients with CRC. The tumor organoids were treated with BBR (20 μg/ml), OPCs (20 μg/ml), and their combination (BBR: 20 μg/ml; OPCs: 20 μg/ml) for 1 week (Figure 6A). It was quite reassuring to witness that the results in this experimental model were consistent with those seen in cell culture experiments, where BBR significantly inhibited the growth and formation of patient-derived organoids compared to untreated ones. Furthermore, the combined treatment with BBR and OPCs enhanced the anti-tumorigenic potentials in patient-derived organoids (FC = 0.50, P = 0.04 in patient #1; FC = 0.50, P = 0.03 in patient #2; Figure 6B). In support of our phenotypic observations made in tumor-derived organoids, the expression of MYB was also significantly down-regulated by the combined treatment of BBR and OPCs (FC = 0.40 vs control, P = 0.05 in patient #1; FC = 0.43 vs control, P = 0.03 in patient #2; Figure 6C). Interestingly, for the expression of apoptosis related genes, Bax was also significantly up-regulated, and Bcl-2 was down-regulated by the combination treatment (Figure 6D). Collectively, these data highlight that the combination treatment with BBR and OPCs possess a remarkable anti-tumorigenic effect in inhibiting organoid growth by enhancing cellular apoptosis and by downregulating the expression of MYB via the PI3K-Akt signaling pathway.

**DISCUSSION**

In treating patients with CRC, overcoming the intrinsic and acquired drug resistance is one of the most challenging problems because chemoresistance leads to frequent cancer recurrence, its dissemination to other organs, and patient death. Furthermore, there is an unequivocal consensus that chemoresistant mutants generally exist as clones at very low numbers before the initiation of chemotherapy. However, following initiation of a single-drug treatment, it often leads to the selection and evolution of such drug-resistant mutational populations of cancer cells, and subsequent treatment with other drugs is usually ineffective due to the establishment of such resistant mechanisms (6, 7). In contrast, combined treatment with multiple drugs presumably impacts multiple pathways, yields a better therapeutic efficacy, which is often attributed to the smaller chances for the emergence of chemoresistance to multiple drugs in cancer cells. However, the therapeutic benefits of combined treatment are usually accompanied by the simultaneous drug toxicity, as well as increased costs – which often limits their clinical efficacy.

To overcome these clinical challenges, the use of safe and cost-effective diet-based natural botanicals offer a time-tested safety and anti-cancer efficacy. Actually, 75 of 175 small molecules recognized as anti-cancer drugs currently, can be traced back to their origin to naturally-occurring botanicals,
from 1981 to 2019 (64). Furthermore, several natural compounds have recently gained increasing attention due to their anti-cancer potential through their ability to target multiple oncogenic pathways, in a safe manner (13–16, 65, 66). Among this list of many such compounds including curcumin, boswellia, resveratrol and andrographis, BBR and OPCs have recently been interrogated due to their promising anti-tumorigenic properties in CRC (30, 32, 33, 35–37). In fact, a recent study also reported a synergistic effect between these two natural compounds in type 2 diabetes mellitus (38). Accordingly, in this study, we for the first time investigated the synergistic anti-tumorigenic effect of BBR and OPCs in CRC by enhancing cellular apoptosis and by downregulating the expression of MYB via the PI3K-Akt signaling pathway (Figure 7), using a series of systematic cell culture and patient-derived tumor organoid experimental models. Furthermore, considering that our observed effects for BBR and OPCs were comparable in microsatellite unstable (MSI) and microsatellite stable (MSS) cell lines, this suggests that these compounds can be used for almost all patients with colorectal cancer; hence highlighting their broader application for this malignancy.

Current evidence has demonstrated the cooperative anti-tumorigenic effects of OPCs with other natural compounds and various chemotherapeutic drugs. Our previous studies also reported that by combining OPCs with curcumin and andrographis, enhanced their growth inhibitory activity in CRC cells (27, 31). In addition, we previously demonstrated the additional ability of OPCs to overcome chemoresistance through the suppression of ABC transporters in CRC (30). In the current study, we build upon our previous work, and illustrate that OPCs also demonstrated synergism with BBR in CRC cells, and in part, this efficacy was perhaps driven by the ability of OPCs to increase the cellular uptake of BBR in cancer cells. Procyanidins including OPCs are considered to downregulate the expression of P-glycoprotein, which is an important protein of the cell membrane that pumps many foreign substances out of cells, by inhibiting NF-kB activation and MAPK/ERK-mediated YB-1 activity (38, 67). These previous studies and our present results suggest that the synergism observed...
between BBR and OPCs might be a result of OPCs to facilitate the increased cellular uptake of BBR by inhibiting the efflux of BBR through the regulation of P-glycoprotein.

The PI3K-Akt signaling pathway plays a vital role in cancer development and drug-resistance, and BBR’s properties on the cell apoptosis through the regulation of this signaling pathway have been illustrated in various types of cancers (68, 69). In osteosarcoma and breast cancer, BBR promoted cellular apoptosis through inhibition of the PI3K-Akt signaling pathway (70, 71). More interestingly, BBR acted synergistically with PI3K inhibitor in SW480 CRC cells (72). In line with previous reports, in our present study, BBR enhanced cellular apoptosis in CRC cells and regulated the PI3K-Akt signaling pathway. Furthermore, the combination of OPCs further enhanced the anti-tumorigenic apoptotic potential of BBR. Within the context of this pathway, MYB, encodes for three types of oncoproteins and functions, is a transcriptional regulator in the PI3K-Akt signaling pathway and considered to be an oncogene that regulates apoptosis (55–58). Accordingly, in this study, we focused on the evaluation of the function of MYB as a potential target in support of the combined treatment with BBR and OPCs. According, in support of several previous reports and our results of siRNA experiments in this study, MYB played an important role in cancer progression and metastases through regulation of apoptosis. Although transcriptional factors are traditionally considered difficult to target, renewed interest in targeting transcriptional factors has opened a new horizon in the field of cancer drug discovery. More specifically, MYB has also emerged as an attractive therapeutic target in cancers, and several small molecules or peptide-mimetic inhibitors have shown promise as anti-cancer agents (61, 62). However, none of these compounds have thus far been used in the clinical practice due to the accompanying toxicity. In this study, we for the first time report that MYB is critically involved in the anti-tumorigenic effects for the
observed anti-cancer effects with BBR and OPCs. Our new findings thus offer a potentially safe alternative to the drug toxicity of MYB-inhibitors, considering the time-tested safety and recently reported anti-cancer efficacy of these nutraceuticals.

In this study, for the first time, we investigated the synergistic anti-tumorigenic effect of BBR and OPCs against CRC cells, however, we would like to acknowledge some of the potential limitations of our work. Since the primary objective of our study
was to investigate the synergism of BBR and OPCs against CRC cells. In addition, given the constraints with tumor-derived organoid, we were able to analyze such organoids from only two patients. Moreover, our pathway analyses were performed in cells treated by BBR alone and OPCs alone, not the combined treatment. While RNA sequencing of the combined treatment might reveal additional genes and pathways that orchestrate the chemopreventive effects of these compounds, the primary objective of the present study was the gain first insights on the synergistic anti-cancer effect of BBR and OPCs against CRC cells. Therefore, we first performed the RNA sequencing in cells treated by BBR alone and OPCs alone. Future studies with such combinatorial treatments and transcriptomic profiling might reveal previously unrecognized genes and regulatory pathways in colorectal cancer. Although, we validated our in vivo findings about the synergism of BBR and OPCs in patient-derived tumor organoids experiments, this study involved no animal studies to demonstrate the toxicity examination. Accordingly, future studies are warranted to further investigate the detailed molecular mechanisms of the combined treatment with BBR and OPCs on MYB and PI3K-Akt signaling pathway, including the validation of our findings in the tumor spheroids and animal models.

CONCLUSIONS

In conclusion, we have firstly demonstrated that the combination treatment of BBR and OPCs promoted the anti-tumorigenic effects in CRC possibly through the inhibition of cellular apoptosis by regulating the expression of MYB in the PI3K-Akt signaling pathway. Our findings could provide essential evidence of the combined treatment with BBR and OPCs as a potential therapeutic option for patients with CRC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
2. Giacchetti S, Perpont B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol (2000) 18(1):136–47. doi: 10.1200/JCO.2000.18.1.136
3. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol (2005) 23(22):4866–75. doi: 10.1200/JCO.2005.07.113
4. Bernards R. A Missing Link in Genotype-Directed Cancer Therapy. Cell (2012) 151(3):665–68. doi: 10.1016/j.cell.2012.10.014
5. Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling Cross-Talk in the Resistance to HER Family Receptor Targeted Therapy. Oncogene (2014) 33(9):1073–81. doi: 10.1038/onc.2013.74
6. Komarova NL, Boland CR. Cancer: Calculated Treatment. Nature (2013) 499(7458):291–2. doi: 10.1038/499291a
7. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers. Nature (2012) 486(7404):537–40. doi: 10.1038/nature11219
8. Bishayee A, Sethi G. Bioactive Natural Products in Cancer Prevention and Therapy: Progress and Promise. Semin Cancer Biol (2016) 40–41:1–3. doi: 10.1016/j.semcancer.2016.08.006

AUTHOR CONTRIBUTIONS

KO, RG, MT, YK, and AG conceived and designed the experiments. KO and RG performed the experiments and analyzed the data. KO and AG wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by, CA184792, CA187956, CA227602, CA072851, and CA202797 grants from the National Cancer Institute, National Institutes of Health.

ACKNOWLEDGMENTS

The authors thank Drs. Kota Nakamura, Souvick Roy, Yogi Pratama, Viktor Hlavac, Nour-Lynn Moulleem, Yu Chen, Zhongxu Zhu, Milad Moloudizargari, Katsuki Miyazaki, and Manikandan Murugesan for their thoughtful discussions and advice during the course of this project. We also thank Ms. Liz Tseng for technical assistance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.855860/full#supplementary-material

Supplementary Figure 1 | Isobologram analysis after combined treatment with BBR and OPCs in RKO and HT29 cells.

Supplementary Figure 2 | (A) CCK-8 assays comparing cell viability following treatment with BBR, OPCs, and their combination for 48 hours in NCM460 cells. Error bars are the mean ± SD. (B) Cell viability following treatment with BBR (20 μg/ml), OPCs (20 μg/ml), and their combination (BBR: 20 μg/ml and OPCs: 20 μg/ml) for 48 hours in NCM460 cells. The average (column) ± SD is indicated.

Supplementary Figure 3 | The qRT-PCR analysis of CDKN1A, F2R, FGF9, and ITGB7 expression in RKO and HT29 cells following treatment with BBR, OPCs, and their combination for 48 hours. Relative expression was calculated using β-Actin mRNA expression as an internal control. The average (column) ± SD is indicated (*P < 0.05, #P < 0.05 vs BBR alone).
9. Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, Srivastava S, et al. Role of Phytochemicals in Cancer Prevention. *Int J Mol Sci* (2019) 20(20):4987. doi: 10.3390/ijms20204987

10. Ghodhrai AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. *Front Pharmacol* (2019) 10:1614. doi: 10.3389/fphar.2019.01614

11. Chávez-Ramírez MH, de la Cruz-López KG, García-Carrancá A. Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways. *Front Pharmacol* (2021) 12:710304. doi: 10.3389/fphar.2021.710304

12. Haque A, Brazeau D, Amin AR. Perspectives on Natural Compounds in Cancer Treatment and Cancer: An Update With New Promising Compounds. *Eur J Cancer* (2021) 149:165–83. doi: 10.1016/j.ejca.2021.03.009

13. Ratajczak K, Borska S. Cytotoxic and Proapoptotic Effects of Resveratrol in In Vitro Studies on Selected Types of Gastrointestinal Cancers. *Molecules* (2021) 26(14):4350. doi: 10.3390/molecules26144350

14. Sampaio LA, Pina LTS, Serafini MR, Tavares DDS, Guimarães AG. Antitumor Effects of Carvacrol and Thymol: A Systematic Review. *Front Pharmacol* (2021) 12:702487. doi: 10.3389/fphar.2021.702487

15. Naji M, Soroudi S, Akaberi M, Sahebkar A, Emami SA. Updated Review on the Role of Curcumin in Gastrointestinal Cancers. *Adv Exp Med Biol* (2021) 1308:55–89. doi: 10.1007/978-3-030-64872-5_6

16. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-Cancer Mechanisms of Berberine: A Review. *Cancer Manag Res* (2020) 12:695–702. doi: 10.2174/CMAR212329

17. Toden S, Goel A. The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern? *J Restor Med* (2017) 6(1):27–36. doi: 10.12400/jrm.2017.6.0101

18. Toden S, Theiss AL, Wang X, Goel A. Essential Turmeric Oils Enhance Antioxidant and Radioprotector for Normal Organs. *Chemosensitizer and Radiosensitizer for Tumors and Chemoprotector and Anti-Tumorigenic Properties in Colorectal Cancer*. *Carcinogenesis* (2019) 38(6):767–77. doi: 10.1038/s41598-019-0257-7

19. Habtemariam S. The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches. *Biomedicines* (2020) 8(4):90. doi: 10.3390/biomedicines8040090

20. Kwon S, Chan AT. Extracting the Benefits of Berberine for Colorectal Cancer. *Lancet Gastroenterol Hepatol* (2020) 5(3):231–3. doi: 10.1016/S2468-1239(19)30430-9

21. Liu Y, Hua W, Li Y, Xian X, Zhao Z, Liu C, et al. Berberine Suppresses Colon Cancer Cell Proliferation by Inhibiting the SCAPl/SREBP-1 Signaling Pathway-Mediated Lipogenesis. *Biochem Pharmacol* (2017) 141:13776. doi: 10.1016/j.bcp.2017.13776

22. Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, et al. Berberine Binds RorX to Suppress β-Catenin Signaling in Colon Cancer Cells. *Oncogene* (2017) 36(50):6906–18. doi: 10.1038/onc.2017.296

23. Zhang H, Wang X, Wang T, Chen K, Wang H, Jia Q, et al. Enhancement of Berberine Hypoglycemic Activity by Oligomeric Proanthocyanidins. *Molecules* (2018) 23(12):3318. doi: 10.3390/molecules23123318

24. Guan X, Zheng X, Vong CT, Zhao J, Xiao J, Wang Y, et al. Combined Effects of Berberine and Emodiavine on Colorectal Cancer Cells and Cardiomyocytes In Vitro. *Eur J Pharmacol* (2020) 875:173031. doi: 10.1016/j.ejphar.2020.173031

25. Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y, et al. Enhancement of Apoptosis of Human Hepatocellular Carcinoma SMMC-7721 Cells Through Synergy of Berberine and Emodiavine. *Phytomedicine* (2008) 15(12):1062–8. doi: 10.1016/j.phymed.2008.05.002

26. Rather MA, Bhat QA, Quirashi MA. Multicomponent Phytotherapeutic Approach Gaining Momentum: Is the ‘One Drug to Fit All’ Model Breaking Down? *Phytopharmacology* (2013) 21(1):1–14. doi: 10.1016/j.phym.2013.07.019

27. Zhang A, Sun H, Wang X. Potentiating Therapeutic Effects by Enhancing Synergism Based on Active Constituents From Traditional Medicine. *Phytother Res* (2014) 28(4):526–33. doi: 10.1002/trr.5032

28. Dai B, Ma Y, Yang T, Fan M, Yu R, Su Q, et al. Synergistic Effect of Berberine and HMQ1611 Impairs Cell Proliferation and Migration by Regulating Wnt Signaling Pathway in Hepatocellular Carcinoma. *Phytother Res* (2019) 33(1):745–55. doi: 10.1002/trr.2020.12:969

29. Pinto-García L, Effert H, Torres A, Hoheisel JD, Youns M. Berberine Inhibits Cell Growth and Mediates Caspase-Independent Cell Death in Human Pancreatic Cancer Cells. *Planta Med* (2020) 76(11):1555–61. doi: 10.1055/s-0030-1249931

30. Chou TC. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. *Cancer Res* (2010) 70(2):440–6. doi: 10.1158/0008-5472.CAN-09-1947

31. Serafini TL, Oliveira PJ, Sardo VA, Perkins E, Parke D, Holy J. Different Concentrations of Berberine Result in Distinct Cellular Localization Patterns and Cell Cycle Effects in a Melanoma Cell Line. *Cancer Chemother Pharmacol* (2008) 62(1):1007–18. doi: 10.1007/s00058-007-0558-9

32. Wang S, An J, Dong W, Wang X, Sheng J, Jia Y, et al. Glucose-Coated Berberine Nanodrug for Glioma Therapy Through Mitochondrial Pathway. *Int J Nanomed* (2020) 15:7951–61. doi: 10.2147/IJN.S213079
48. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 25(4):402–8. doi: 10.1038/sj.mp.6001513

49. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: The Reference Human Genome Annotation for The ENCODE Project. Genome Res (2012) 22(9):1760–70. doi: 10.1101/gr.135350.111

50. Kim D, Langmead B, Salzberg SL. HISAT: A Fast Spliced Aligner With Low Memory Requirements. Nat Methods (2015) 12(4):357–60. doi: 10.1038/nmeth.3317

51. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map Format and SAMtools. Bioinformatics (2009) 25(16):2078–9. doi: 10.1093/bioinformatics/btp352

52. Anders S, Pyl PT, Huber W. HTSeq—a Python Framework to Work With High-Throughput Sequencing Data. Bioinformatics (2015) 31(2):166–9. doi: 10.1093/bioinformatics/btu638

53. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2. Genome Biol (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8

54. Kanda Y. Investigation of the Freely Available Easy-to-Use Software ‘EZR’ for Medical Statistics. Bone Marrow Transplant (2013) 48(3):452–8. doi: 10.1038/bmt.2012.244

55. Grassilli E, Salomoni P, Perrotti D, Franceschi C, Calabretta B. Resistance to Apoptosis in CLL-2 Cells Overexpressing B-Myb is Associated With B-Myb-Dependent Bcl-2 Induction. Cancer Res (1999) 59(10):2451–6

56. Selvakumaran M, Lin HK, Sjin RT, Reed JC, Liebermann DA, Hoffman B. The Novel Primary Response Gene MyD118 and the Proto-Oncogenes Myb, Myc, and Bcl-2 Modulate Transforming Growth Factor Beta 1-Induced Apoptosis of Myeloid Leukemia Cells. Mol Cell Biol (1994) 14(4):2352–60. doi: 10.1128/mcb.14.4.2352-2360.1994

57. Biroccio A, Benassi B, D’Agnano L, D’Angelo C, Buglioni S, Mottollese M, et al. C-Myb and Bcl-X Overexpression Predicts Poor Prognosis in Colorectal Cancer: Clinical and Experimental Findings. Am J Pathol (2001) 158(4):1289–99. doi: 10.1016/S0002-9440(10)64080-1

58. Drabsch Y, Robert RG, Gonda TJ. MYB Suppresses Differentiation and Apoptosis of Human Breast Cancer Cells. Breast Cancer Res (2010) 12(4): R55. doi: 10.1186/bcr2614

59. Qu X, Yan X, Kong C, Zhu Y, Li H, Pan D, et al. C-Myb Promotes Growth and Metastasis of Colorectal Cancer Through C-Fos-Induced Epithelial-Mesenchymal Transition. Cancer Sci (2019) 110(10):3183–96. doi: 10.1111/cas.14141

60. Fan X, Wang Y, Jiang T, Liu T, Jin Y, Du K, et al. B-Myb Accelerates Colorectal Cancer Progression Through Reciprocal Feed-Forward Transactivation of E2F2. Oncogene (2021) 40(37):5613–25. doi: 10.1038/s41388-021-01961-9

61. Cicirò Y, Sala A. MYB Oncoproteins: Emerging Players and Potential Therapeutic Targets in Human Cancer. Oncogenesis (2021) 10(2):19. doi: 10.1038/s41389-021-00309-y

62. Mitra P. Transcription Regulation of MYB: A Potential and Novel Therapeutic Target in Cancer. Ann Transl Med (2018) 6(22):443. doi: 10.21037/atm.2018.09.62

63. Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor Organoids as a Pre-Clinical Cancer Model for Drug Discovery. Cell Chem Biol (2017) 24(9):1092–100. doi: 10.1016/j.chembiol.2017.06.012

64. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs Over the Nearly Four Decades From 01/1981 to 09/2019. J Nat Prod (2020) 83(3):770–803. doi: 10.1021/acs.jnatprod.9b01285

65. Xu Z, Du P, Meiser P, Jacob C. Proanthocyanidins: Oligomeric Structures With Unique Biochemical Properties and Great Therapeutic Promise. Nat Prod Commun (2012) 7(3):381–8. doi: 10.1177/1934578X1200700321

66. Tariq A, Sadia S, Pan K, Ullah I, Mussarat S, Sun F, et al. A Systematic Review on Ethnomedicines of Anti-Cancer Plants. Phytother Res (2017) 31(2):202–64. doi: 10.1002/ptr.5751

67. Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL, Ren F, et al. Grape Seed Procyanidin Reversal of P-Glycoprotein Associated Multi-Drug Resistance via Down-Regulation of NF-xb and MAPK/ERK Mediated YB-1 Activity in A2780/T Cells. PLoS One (2013) 8(8):e71071. doi: 10.1371/journal.pone.0071071

68. Huang J, Huang J, Feng W, Li S, Tang H, Qin S, Li W, et al. Berberine Exerts Anti-Cancer Activity by Modulating Adenosine Monophosphate-Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) Signaling Pathways. Curr Pharm Des (2021) 27(4):565–74. doi: 10.2174/138161282666200928155728

69. Farooqi AA, Qureshi MZ, Khalid S, Attar R, Martinelli C, Sabatiljevich YU, et al. Regulation of Cell Signaling Pathways by Berberine in Different Cancers: Searching for Missing Pieces of an Incomplete Jig-Saw Puzzle for an Effective Cancer Therapy. Cancers (Basel) (2019) 11(4):478. doi: 10.3390/cancers1104047

70. Chen ZZ. Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/AKT) Signal Pathway Activation. Iran J Public Health (2016) 45(5):578–85.

71. Kuo HP, Chuang TC, Yeh MH, Hsu SC, Way TD, Chen PY, et al. Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway. J Agric Food Chem (2011) 59(15):8216–24. doi: 10.1021/jf2012854

72. Li G, Zhang C, Liang W, Zhang Y, Shen Y, Tian X. Berberine Regulates the Notch1/PTEN/PI3K/AKT/Pathway and Acts Synergistically With 17-AAG and SAHA in SW480 Colon Cancer Cells. Pharm Biol (2021) 59(1):21–30. doi: 10.1080/13880209.2020.1865407

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Okuno, Garg, Yuan, Tokunaga, Kinugasa and Goel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.